234 related articles for article (PubMed ID: 15102561)
21. A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis.
Touchette DR; Durgin TL; Wanke LA; Goodkin DE
Clin Ther; 2003 Feb; 25(2):611-34. PubMed ID: 12749517
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of mitoxantrone for the treatment of multiple sclerosis.
Jain KK
Expert Opin Investig Drugs; 2000 May; 9(5):1139-49. PubMed ID: 11060734
[TBL] [Abstract][Full Text] [Related]
23. Mitoxantrone (Novantrone) in multiple sclerosis: new insights.
Neuhaus O; Kieseier BC; Hartung HP
Expert Rev Neurother; 2004 Jan; 4(1):17-26. PubMed ID: 15853611
[TBL] [Abstract][Full Text] [Related]
24. Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.
Rivera VM; Jeffery DR; Weinstock-Guttman B; Bock D; Dangond F
BMC Neurol; 2013 Jul; 13():80. PubMed ID: 23841877
[TBL] [Abstract][Full Text] [Related]
25. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
Foo EC; Russell M; Lily O; Ford HL
Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
[TBL] [Abstract][Full Text] [Related]
26. [Recent advances in the pathogenesis and immunotherapy of multiple sclerosis].
Gold R; Rieckmann P
Nervenarzt; 2007 Sep; 78 Suppl 1():15-24; quiz 25. PubMed ID: 17668159
[TBL] [Abstract][Full Text] [Related]
27. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
28. Escalating immunotherapy with mitoxantrone in patients with very active relapsing-remitting or progressive multiple sclerosis.
Cursiefen S; Flachenecker P; Toyka KV; Rieckmann P
Eur Neurol; 2000; 43(3):186-7. PubMed ID: 10765063
[No Abstract] [Full Text] [Related]
29. Mitoxantrone versus cyclophosphamide in secondary-progressive multiple sclerosis: a comparative study.
Perini P; Calabrese M; Tiberio M; Ranzato F; Battistin L; Gallo P
J Neurol; 2006 Aug; 253(8):1034-40. PubMed ID: 16609811
[TBL] [Abstract][Full Text] [Related]
30. Mitoxantrone immunotherapy in multiple sclerosis.
Gonsette RE
Mult Scler; 1996 Jul; 1(6):329-32. PubMed ID: 9345411
[TBL] [Abstract][Full Text] [Related]
31. Mitoxantrone for multiple sclerosis.
Martinelli Boneschi F; Rovaris M; Capra R; Comi G
Cochrane Database Syst Rev; 2005 Oct; (4):CD002127. PubMed ID: 16235298
[TBL] [Abstract][Full Text] [Related]
32. Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity.
Gonsette RE; Dubois B
J Neurol Sci; 2004 Aug; 223(1):81-6. PubMed ID: 15261566
[TBL] [Abstract][Full Text] [Related]
33. Mitoxantrone therapy in rapidly worsening multiple sclerosis.
Benesova Y; Stourac P; Beranek M; Kadanka Z
Bratisl Lek Listy; 2005; 106(3):141-3. PubMed ID: 16026151
[TBL] [Abstract][Full Text] [Related]
34. FDA backs cancer drug for treating MS.
Case Manager; 2000; 11(2):22. PubMed ID: 11935515
[No Abstract] [Full Text] [Related]
35. Immunologic therapy for relapsing-remitting multiple sclerosis.
MacLean HJ; Freedman MS
Curr Neurol Neurosci Rep; 2001 May; 1(3):277-85. PubMed ID: 11898530
[TBL] [Abstract][Full Text] [Related]
36. Clinical follow-up of 304 patients with multiple sclerosis three years after mitoxantrone treatment.
Debouverie M; Taillandier L; Pittion-Vouyovitch S; Louis S; Vespignani H
Mult Scler; 2007 Jun; 13(5):626-31. PubMed ID: 17548442
[TBL] [Abstract][Full Text] [Related]
37. [Combined therapy of aggressive remitted multiple sclerosis with mitoxantrone in combination with copaxone].
Sazonov DV; Malkova NA; Bulatova EV; Riabukhina OV
Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(12):76-9. PubMed ID: 20037526
[TBL] [Abstract][Full Text] [Related]
38. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.
Le Page E; Leray E; Taurin G; Coustans M; Chaperon J; Morrissey SP; Edan G
J Neurol Neurosurg Psychiatry; 2008 Jan; 79(1):52-6. PubMed ID: 17846110
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic role of mitoxantrone in multiple sclerosis.
Neuhaus O; Kieseier BC; Hartung HP
Pharmacol Ther; 2006 Jan; 109(1-2):198-209. PubMed ID: 16095713
[TBL] [Abstract][Full Text] [Related]
40. Treatment of multiple sclerosis and related disorders: what's new in the past 2 years?
Noseworthy JH
Clin Neuropharmacol; 2003; 26(1):28-37. PubMed ID: 12567162
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
